Jmcll: While it's a nice thought, I think the adv

Jmcll: While it's a nice thought, I think the advertising and PR of CytoDyn is best left to the company. Let them do what they do, because they have far more information than we do and believe me, they have a vested interest in Leronlimab making as big a splash as possible, AT THE RIGHT TIME.